Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

  • IMMU-132 for Metastatic Urothelial Cancer

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)


Breast

Colon

Gastrointestinal

  • Study of Carbo/Paclitaxel + INCMGA00012/Placebo in Squamous Cell Carcinoma of the Anal Canal

    A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy


  • Phase 3 Study of INCMGA00012 in Anal Cancer

    A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy


Hematology

Leukemia

Lung

Lymphoma

Melanoma

Ovarian

Pancreatic

Prostate

Renal

Solid Tumors